Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus

Background: To evaluate the immunogenicity and safety of the COVID-19 vaccine (Vero cell), inactivated, in a population aged ≥60 years with hypertension or(/and) diabetes mellitus. Methods: A total of 1440 participants were enrolled and divided into four groups, 330 in the hypertension group, 330 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuntao, Chen, Haiping, Lv, Jun, Huang, Tao, Zhang, Ruizhi, Zhang, Dongjuan, Luo, Linyun, Wei, Sheng, Liu, Xiaoqin, Zhang, Shangxiao, Mu, Qiuyue, Huang, Rongdong, Huang, Jiao, Xiao, Yanhui, Yang, Yunkai, Han, Yuting, Gong, Hao, Guan, Qinghu, Xie, Fangqin, Wang, Hui, Li, Liming, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315836/
https://www.ncbi.nlm.nih.gov/pubmed/35891184
http://dx.doi.org/10.3390/vaccines10071020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315836/
https://www.ncbi.nlm.nih.gov/pubmed/35891184
http://dx.doi.org/10.3390/vaccines10071020

Ejemplares similares